Last reviewed · How we verify
Etoposid
At a glance
| Generic name | Etoposid |
|---|---|
| Sponsor | University of Ulm |
| Target | Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant tumor of testis
- Small cell carcinoma of lung
- Treatment prior to tumor-specific T-cell infusion therapy
Common side effects
- Myelosuppression
- Nausea/Vomiting
- Alopecia
- Hypersensitivity
- Fatigue
- Fever
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Anorexia
- Abdominal Pain
Serious adverse events
- Anaphylactic Reaction
- Secondary Leukemia/Acute Leukemia
- Severe Myelosuppression
- Pulmonary Fibrosis
- Interstitial Pneumonitis
- Stevens-Johnson Syndrome (SJS)
- Toxic Epidermal Necrolysis (TEN)
- Extravasation with Tissue Necrosis
- Febrile Neutropenia
- Seizure
Key clinical trials
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors (PHASE2)
- Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia (NA)
- Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma (PHASE3)
- All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE3)
- Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia (PHASE3)
- ALL-SCT BFM International- HSCT in Children and Adolescents With ALL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etoposid CI brief — competitive landscape report
- Etoposid updates RSS · CI watch RSS
- University of Ulm portfolio CI